Biotech Values

[genisi]

SGEN/vedotin (SGN-35) in ALCL :

http://www.marketwatch.com/story/seattle-genetics-and-millennium-announce-positive-top-line-brentuximab-vedotin-sgn-35-data-from-phase-ii-trial-in-relapsed-or-refractory-alcl-2010-10-11?reflink=MW_news_stmp

"...Eighty-six percent of patients in the trial achieved an objective response as assessed by an independent central review. Overall response rate, including both complete and partial remissions, is the primary endpoint of the study. The median duration of response has not yet been reached at a median follow up on study of approximately six months."